Document is current
Any future updates will be listed below
-
Authors
Taavitsainen, S. https://orcid.org/0000-0001-7559-9853
Engedal, N. https://orcid.org/0000-0003-3718-3464
Cao, S.
Handle, F. https://orcid.org/0000-0002-7558-5635
Erickson, A.
Prekovic, S. https://orcid.org/0000-0002-7051-9321
Wetterskog, D.
Tolonen, T. https://orcid.org/0000-0003-2029-6497
Vuorinen, E. M. https://orcid.org/0000-0002-1320-0621
Kiviaho, A. https://orcid.org/0000-0001-7419-0773
Nätkin, R.
Häkkinen, T.
Devlies, W.
Henttinen, S.
Kaarijärvi, R.
Lahnalampi, M. https://orcid.org/0000-0003-4050-4935
Kaljunen, H. https://orcid.org/0000-0002-5962-9503
Nowakowska, K.
Syvälä, H.
Bläuer, M.
Cremaschi, P.
Claessens, F. https://orcid.org/0000-0002-8676-7709
Visakorpi, T.
Tammela, T. L. J.
Murtola, T.
Granberg, K. J. https://orcid.org/0000-0001-6549-7810
Lamb, A. D. https://orcid.org/0000-0002-2968-7155
Ketola, K.
Mills, I. G.
Attard, G. https://orcid.org/0000-0002-4811-7983
Wang, W. https://orcid.org/0000-0003-0617-9438
Nykter, M. https://orcid.org/0000-0001-6956-2843
Urbanucci, A. https://orcid.org/0000-0003-2931-3652
-
Funding
Funding for this research was provided by:
Kreftforeningen (198016-2018, 198016-2018)
Academy of Finland (312043)
- License Information
-
More Information
Article History
Received: 1 April 2021
Accepted: 23 August 2021
First Online: 6 September 2021
Competing interests
: GA receives a reward from the Institute of Cancer Research for his role as an inventor of abiraterone. GA has received honoraria, consulting fees, or travel support from Janssen, Astellas, Pfizer, Novartis, Bayer, Amgen, AstraZeneca, Sanofi, and Sapience, grant support from Janssen and Astellas, and is a principal investigator for clinical trials sponsored by Janssen, Pfizer, and Astellas. TM receives consultant fees from Astellas, Janssen, and Bayer; lecture fees from Novartis, Janssen, and Sanofi. He is a stockholder of Arocell ab. The remaining authors declare no competing interests.
